PREPARATION AND CHARACTERIZATION OF AN ELECTROSPUN  GELATIN/DENDRIMER HYBRID NANOFIBER DRESSING by Smith-Freshwater, Alicia P.
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2009
PREPARATION AND CHARACTERIZATION
OF AN ELECTROSPUN GELATIN/
DENDRIMER HYBRID NANOFIBER
DRESSING
Alicia P. Smith-Freshwater
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Biomedical Engineering and Bioengineering Commons
© The Author
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/19
School of Engineering  
Virginia Commonwealth University  
 
 
This is to certify that the thesis prepared by Alicia Smith-Freshwater entitled  
PREPARATION AND CHARACTERIZATION OF AN ELECTROSPUN 
GELATIN/DENDRIMER  HYBRID NANOFIBER DRESSING  FOR CHRONIC 
WOUND tREATMENT  has been approved by her committee as satisfactory completion 
of the thesis requirement for the degree of Master of Science in Biomedical Engineering 
 
 
 
 
Hu Yang, Ph.D., Thesis Director, Department of Biomedical Engineering  
 
 
 
Gary L. Bowlin, Ph.D., Department of Biomedical Engineering 
 
 
Thomas W. Haas, Ph.D., Department of Biomedical Engineering 
 
W. Andrew Yeudall, Ph.D., School of Dentistry 
 
 
Gerald E. Miller, Ph.D., Chair, Department of Biomedical Engineering 
 
 
Rosalyn Hobson, Ph.D., Associate Dean of Graduate Studies, School of Engineering 
 
 
Russell D. Jamison, Ph.D., Dean of School of Engineering 
 
 
Douglas F. Boudinot, Ph.D., Dean of the Graduate School 
 
 
August 14, 2009. 
 
 
© Alicia Smith-Freshwater 2009 
All Rights Reserved 
 
 
 
 
 
 
 
 
PREPARATION AND CHARACTERIZATION OF AN ELECTROSPUN                            
GELATIN/DENDRIMER HYBRID NANOFIBER DRESSING 
 FOR CHRONIC WOUND TREATMENT 
 
 
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science in Biomedical Engineering at Virginia Commonwealth University 
 
 
By 
 
Alicia P. Smith-Freshwater 
Bachelor of Science, North Carolina Agricultural & Technical State University, 1992 
 
Director: Hu Yang, Ph.D., Assistant Professor, Biomedical Engineering
 
 
 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia  
August 14, 2009 
 
 
Acknowledgment 
 
I would like to thank my research advisor, Dr. Hu Yang for his exemplary tutelage, 
innovative ideas and guidance throughout the course of this research. A constant inspiration, Dr. 
Yang’s expertise and knowledge bolstered the foundation of learning. I would also like to thank 
the members of my thesis committee, Dr. Gary Bowlin, Dr. Thomas Haas and Dr. Andrew 
Yeudall, for their efforts in reviewing and evaluating my research. Sincere thanks to the College 
of Engineering at Virginia Commonwealth University, and the Southern Regional Education 
Board for financially supporting my quest for higher learning.   I especially thank Pooja Desai, 
Arunvel Kailasan, Scott Sell and Quan Yuan for their assistance, helpful insights and invaluable 
suggestions throughout my matriculation at Virginia Commonwealth University. 
 I dedicate this achievement to my natal and spiritual families- my life partner, M. D. 
Freshwater, for his enduring and selfless support, my daughter, S. Josiah who gives my life 
significance and my angels- Gabriel and Jaedon, who departed this world in journey to the next.   
I am most grateful to my parents, Alonza and Rebecca Smith, for instilling in me the belief that I 
can attain my heart’s desire.  I applaud the commendable support and inspiration of my siblings, 
Alonzo, Erica, Monica, Rosiland, and Tonya, as well as my best friends- Dana, Eugene and 
Exter. They set the bar high- challenging me to climb higher heights.  I especially thank Mount 
Pleasant Evangelistic Church shepherded by Elder Arnold L. Friend, Jr., for diligently praying 
with belief and love that this milestone would be achieved.  May we all continue to lift as we 
climb, striving for a better time than now. 
 
 
Table of Contents 
Page 
Acknowledgments............................................................................................................... ii 
List of Tables ..................................................................................................................... vi 
List of Figures ................................................................................................................... vii 
Chapter 
1 Introduction........................................................................................................1 
2 Background........................................................................................................3 
Chronic Wounds  ..........................................................................................3 
 Normal Wound Healing ..........................................................................3 
 Chronic Wounds and Matrix Metalloproteinases....................................4 
 Healing and Treatment ............................................................................6 
Dendrimers for Drug Delivery ......................................................................8 
 Structure of PAMAM Dendrimers ..........................................................8 
 Synthesis of PAMAM Dendrimers .......................................................10 
 Drug Delivery Mechanisms...................................................................11 
Poly (-Hydroxy Esters) .............................................................................12 
 Poly (-Caprolactone)............................................................................13 
 Poly (Glycolic Acid) .............................................................................14 
 Poly (Lactic-Co-Glycolic Acid) ............................................................15 
iv 
 
Wound Dressings ........................................................................................16 
 Traditional and Emerging Dressings .....................................................17 
 Electrospun Gelatin Co-Polymer Dressing with Doxycycline..............19 
3 Experimental Materials and Methods ..............................................................22 
Materials ......................................................................................................22 
Equipment ...................................................................................................23 
Synthesis......................................................................................................24 
 Conjugation of Gelatin to PAMAM Dendrimer G3.5...........................24 
 Conjugation of Doxycycline to PAMAM Dendrimer G3.5.………….25 
 Encapsulation of Doxycycline.......................................................……26 
 Polymer-Gelatin Spin Dope Solutions ..................................................27 
 Electrospinning Wound Dressings ........................................................27 
 Characterization ...............................................................................................28 
 Ninhydrin Assay....................................................................................28 
 1H-NMR Spectroscopy..........................................................................29 
 Mechanical Property/Tensile Testing....................................................30 
 Scanning Electron Microscopy (SEM) and Fiber Diameter .................30 
 Porosity Measurements .........................................................................31 
 Permeability Measurements ..................................................................31 
      
 
v 
 
 Absorption and Water Swelling Behavior.............................................32 
      In Vitro Degradation .............................................................................33 
      Drug Release Kinetics ...........................................................................33 
      Statistical Analyses................................................................................36 
4 Results and Discussion ....................................................................................38 
Preparation and Characterization of Dendritic G3.5-DC Nanoparticles….38 
Gelatin/Dendrimer Hybrid Morphology .....................................................43 
Dressing Permeability and Porosity ............................................................48 
Drug Encapsulation and Controlled Release...............................................55 
Conclusions .................................................................................................58 
5 Summary and Future Work..............................................................................60 
Summary .....................................................................................................60 
Future Work ...............................................................................................61 
 Cell Interaction and Proliferation Studies .............................................62 
 Synthesis of an Electrospun Wound Dressing with Growth Factor. .....62 
      Drug Selection to Eradicate Biofilm Formation in Chronic Wounds . .63 
Literature Cited ..................................................................................................................64 
Appendix............................................................................................................................71 
 
vi 
 
 
 
List of Tables 
Page 
Table 1: Four Distinct Stages of Chronic Wound Progression............................................6 
Table 2: Polymer Properties for Biomaterials. ..................................................................13 
Table 3: Various Categories to Classify Dressing Type....................................................17 
Table 4: Different Dressings for Chronic Wound Management........................................19 
Table 5: Proposed versus Contemporary Wound Dressings..............................................21 
Table 6: List of Materials...................................................................................................22 
Table 7: List of Equipment . ..............................................................................................23 
Table 8: Mechanical Properties of Electrospun Gelatin. ...................................................43 
Table 9: Mechanical Properties of Gelatin/Dendrimer Hybrids. .......................................45 
Table 10: Summary of Gelatin/Polymer Matrix Fluid Flow Capability ...........................49 
 
 
 
vii 
 
List of Figures  
Page 
Figure 1: Normal versus Chronic Wound Healing. .............................................................5 
Figure 2: Chemical Structure of PAMAM (G2.0) Dendrimer   ..........................................9 
Figure 3: Conjugation Reaction of Gelatin to G3.5 Dendrimer.........................................24 
Figure 4: Proposed Conjugation Reaction of DC to G3.5 Dendrimer...............................26 
Figure 5: General Electrospinning Apparatus....................................................................28 
Figure 6: Standard Calibration Curve for Gelatin (Ninhydrin Assay)...............................29 
Figure 7: Analytical Set-up for Drug Release Kinetics .....................................................33 
Figure 8: UV- Visible Scan of DC.....................................................................................35 
Figure 9: Standard Calibration Curve for DC (190nm) .....................................................35 
Figure 10: Schematic of Reaction to Form an Amide Bond ..............................................38 
Figure 11: Schematic of Steglich Esterification to Form an Ester Bond...........................39 
Figure 12: 1H -NMR of DC-PAMAM G3.5 ......................................................................39 
Figure 13: SEM of PAMAM G3.5 and G4.0 Scaffolds.....................................................41 
Figure 14: Fiber Diameter of G3.5 and G4.0 Scaffolds.....................................................42 
Figure 15: SEM of Electrospun Gelatin.............................................................................43 
Figure 16: SEM Photographs of Polymer Blends..............................................................44 
Figure 17: Graphical Summary of Fiber Diameter, Stress, Strain.....................................46 
Figure 18: Gelatin/Polymer Dressing - Porosity................................................................50 
 
viii 
 
 
Figure 19: Gelatin/Polymer Dressing - Permeability.........................................................51 
Figure 20: Gelatin/Polymer Dressing – Swelling Rate......................................................52 
Figure 21: Gelatin/Polymer Dressing – Average Swelling Behavior................................52 
Figure 22: Theoretical Bulk Degradation Sequence..........................................................53 
Figure 23: Gelatin/Polymer Dressing – Degradation.........................................................54 
Figure 24: Drug Release Kinetics ......................................................................................56 
 
 
 
 
Abstract 
 
 
 
PREPARATION AND CHARACTERIZATION OF AN ELECTROSPUN                            
GELATIN/DENDRIMER HYBRID NANOFIBER DRESSING 
 FOR CHRONIC WOUND TREATMENT 
By Alicia Smith-Freshwater 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science in Biomedical Engineering at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2009 
 
Director: Hu Yang, Ph.D., Assistant Professor, Biomedical Engineering
 
 
A novel dendritic wound dressing was designed and characterized for its potential 
to treat chronic wounds.    Comprised of gelatin, dendrimer, synthetic polymer and 
antibiotics, the dressing was electrospun to mimic the natural extracellular matrix (ECM).  
Gelatin is biocompatible, biodegradable, non-toxic, and easily available. The antibiotic, 
doxycycline, has the ability to inhibit matrix metalloproteinases.  Matrix 
metalloproteinases, which occur in excess in chronic wounds, degrade the reconstituted 
ECM.    Starburst™ polyamidoamine (PAMAM) dendrimer G3.5, which provides a 
versatile and structurally controlled architecture to construct nanomedicine, was covalently 
bonded to the gelatin backbone and electrospun into nanofibers with gelatin, doxycycline 
and stabilizing polymers.  The proposed gelatin/dendrimer hybrid provides a bacterial free 
 environment and mimics the ECM to promote wound healing.  The development of this 
new polymeric matrix is an important step in advancing the use of bioactive nanofibers 
with targeted and controlled drug delivery as a wound dressing. 
  
 
 CHAPTER 1 Introduction 
 
Chronic wounds, also interchangeably termed decubitus ulcers, are one of the 
major health concerns worldwide.  The occurrence of chronic wounds, which are prevalent 
in elderly patients who are bedfast or patients with poor circulation, paralysis or 
compromised immune systems, is on the rise.1   There are a number of causes for this 
increased incident rate of chronic wounds.  Medical advances have resulted in prolonged 
and improved quality of life for quadric- and paraplegics, as well as individuals with 
chronic illnesses like diabetes.  The increasing elderly population and incidence of diabetes 
mellitus provide the impetus to achieve cutting edge advances in the treatment and healing 
of chronic wounds. 2  
The treatment costs of patients with non-healing wounds are significant and 
necessitate aggressive intervention. This intervention is imperative to decrease morbidity 
and reduce treatment costs. Yet, the treatment of chronic wounds is both challenging and 
complex, largely due to prolonged healing resulting from the extended chronic 
inflammation phase of the wound healing process.   This extended phase of chronic wound 
healing results in infiltration of excessive amounts of neutrophils at the wound site. 3  
Neutrophils produce matrix metalloproteinases (MMP), which are destructive proteolytic 
enzymes responsible for degrading the ECM.4    Matrix metalloproteinases are also 
essential to wound healing as they facilitate cell migration and new tissue formation.   Too 
much MMP-8 creates an imbalance and results in degradation of new/regenerated ECM.   
1 
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Contemporary chronic wound dressings are designed to create and retain a moist 
environment around the wound bed to facilitate wound healing. 5   Classified by 
composition, wound dressings include hydrocolloids, alginates, and hydrogels in the form 
of thin films or fibers, foam sheets and gelatins.  Their use is augmented by medicated 
creams and antibiotic ointments. 
The proposed treatment protocol involves the fabrication and application of an 
electrospun gelatin/dendrimer hybrid having PAMAM G3.5 and encapsulated therapeutic 
drugs.  PAMAM G3.5 is a highly branched structure with surface groups that are easily 
modified. Doxycycline (DC) is an effective antibiotic with the added ability to inhibit 
MMPs; thus facilitating wound healing. 6   Gelatin was selected as it is more readily 
available than collagen.  Further, gelatin has many attractive properties as a biomaterial 
such as its biological origin, biodegradability, and biocompatibility.7   Four different 
scaffolds were fabricated for this study.  The control scaffold was gelatin [100 mg/mL], 
and the three evaluation scaffolds were gelatin-dendrimer and encapsulated Doxycycline 
electrospun with poly(-caprolactone), poly(glycolic acid) and poly(lactic-co-glycolic 
acid), respectively.    A major objective of this study was to identify the critical parameters 
to fabricate a gelatin/dendrimer hybrid with optimum fiber size, mechanical strength and 
porosity to be used to treat chronic wounds.  A secondary objective was to determine if 
controlled drug release of DC could be achieved using the designed gelatin-dendrimer drug 
delivery system. 
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CHAPTER 2 Background 
2.1 Chronic Wounds 
2.1.1  Normal Wound Healing   
Wounds are the result of chemical, physical or thermal damage to the skin, blood 
vessel or other bodily organ. 8   This damage manifests itself as a break or defect in the 
skin, blood vessel, etc. Illnesses or physiological conditions, such as chicken pox or a 
hematoma, can also result in a wound. Regardless of whether the damage to the skin is the 
result of a cut, tear, puncture or contusion from blunt force trauma, the body’s response to 
the injury is convoluted yet systematically organized.  
  Normal wound healing is usually described using four distinct phases beginning 
with (1) hemostasis, (2) inflammation, (3) proliferation and (4) remodeling. 9  Hemostasis 
involves clotting to stem bleeding via a temporary fibrin blood clot.  The second phase 
involves acute and chronic inflammation.  Acute inflammation is of short duration and 
primarily involves phagocytosis of microorganisms and foreign materials by neutrophils.  
Exudation to provide an influx of fluid, plasma proteins and blood cells to the injured 
tissue site is also a major activity in acute inflammation.  Chronic inflammation is 
characterized by continued phagocytosis via macrophages that also induce the release of 
neutral proteases, chemotactic factors, reactive oxygen metabolites and growth factors.  
Connective tissue and blood vessel proliferation is also initiated.  In the proliferation 
phase, transforming growth factor beta (TGF-) yields increased transcription of genes for 
synthesis of collagen, proteoglycans and fibronectin; but most importantly decreases the 
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protease responsible for the breakdown of matrix proteins. 10    The final phase, 
remodeling, is characterized by the synthesis and degradation of ECM components to 
establish a new equilibrium.  
 2.1.2 Chronic Wounds and Matrix Metalloproteinases   
Chronic wounds represent a significant cause of morbidity and mortality for adult 
patients experiencing diabetes, cancer, malnutrition, physical disabilities (e.g. paralysis), 
and compromised immunity due to illnesses like HIV/AIDS. 11   Non-healing wounds do 
not progress through the stages of normal wound healing due to the self-sustaining cycle of 
chronic inflammation leading to the destruction of the ECM. 12   Matrix metalloproteinases 
are enzymes that are involved in tissue reorganization, inflammation and remodeling. 
Sixteen MMPs have been identified and characterized for substrate specificity. 13      
Failure of MMP regulation has been correlated with deficient wound healing, such as 
chronic wound healing.   Chronic non-healing ulcers were characterized by significantly 
higher levels of MMP-1 and MMP-8 and lower levels of tissue inhibitor of 
metalloproteinase 1 (TIMP-1) in a comparison of chronic non-healing ulcers to normal 
healing wounds.  Studies have shown that the over-expression and activation of neutrophil-
derived MMP-8 is involved in the pathogenesis of nonhealing chronic ulcers. 14     
Wounds are classified as either acute or chronic.  Acute wounds usually result from 
disruption to the tissue, yet heal completely in the expected time-frame of eight to 12 
weeks, and with minimal scarring12.  However, chronic wounds that develop from tissue 
injuries are slow to heal, and have not healed within the expected 12 week timeframe.  
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Chronic wound healing is impeded by repeated tissue insults or underlying physiological 
conditions like diabetes, poor blood circulation or persistent infections15.   Chronic wounds 
are impeded by extended inflammation where the balance of ECM degradation and 
synthesis is compromised by the excessive amounts of neutrophils thus generating 
increased levels of MMPs.  Figure 1 is a schematic adapted from Nwomeh et al., 
summarizing key differences in normal and chronic wound healing.  12   As noted in the 
diagram, the amount of neutrophils increases, therefore increasing matrix degradation due 
to MMP.  Additionally, protease inhibitors are decreased, which allows even further matrix 
degradation.  The degradation occurs not only of the damaged ECM and tissue, but 
reconstituted matrix is also degraded. 
Figure 1: Normal versus Chronic Wound Healing 
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2.1.3 Healing and Treatment   
The majority of chronic wounds are pressure ulcers (bed stores), diabetic foot 
ulcers and venous stasis ulcers, with the latter accounting for 70% of chronic wounds. 16      
A pressure ulcer is a break in the skin and is commonly located in the posterior and ischial 
sections of the pelvis, the heel or the upper part of the femur.  Pressure ulcers are caused by 
ischemia that occurs when pressure on the tissue is greater than the pressure in capillaries, 
thus restricting blood flow into the area. 17   They occur due to friction and external 
pressure in the elderly, and patients that are bed-ridden or have spinal cord 
injuries/paralysis.   Chronic wounds develop in four distinct stages. 18  These four stages 
influence the treatment protocol and are listed in Table 1.   
Table 1: Four Distinct Stages of Chronic Wound Progression 
Stage General Characteristics 
Stage I 
Reddened area on the skin; no break. Non-blanchable when pressed; and 
coloration is pink, red, or mottled after pressure is relieved. Patients with 
darker pigmentation have subtle purplish or extra discoloration. 
Stage II 
Partial loss of skin thickness. Skin blisters and forms an open sore.  The 
area is broken, cracked, blistered, and mottled in color. Necrotic tissue or 
drainage may also be present. 
Stage III Full loss of skin thickness. Skin breakdown (i.e. crater); tissue damage may be necrotic (black), draining (yellow), or granulating (red). 
Stage IV Deep pressure ulcer, muscle, bone tendon or joint damage.  Damage may have extensive drainage and necrotic tissue. 
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Current and emerging chronic wound treatments are designed to alleviate some of 
the causes responsible for delayed healing.   Methods for wound repair include mitigation 
of the primary causes like external pressure, ischemia, bacterial load and protease 
imbalance.   The application and use of antibiotics and antibacterial agents, debridement, 
irrigation, vacuum-assisted closure, oxygenation, moist wound healing and addition of 
cells and growth factors are various methods used to advance healing of chronic wounds. 19    
The treatment protocol for Stage I pressure ulcers involves decreasing or 
eliminating the external pressure source, reducing moisture from incontinence, employing 
pressure relief devices, and ensuring adequate patient hydration and nutrition.  To prevent 
bacterial invasion, transparent film, foam or hydrocolloid dressings are applied.20   The 
primary function of the temporary dressings is to serve as a barrier, much like human skin.   
Dressings to treat Stage II ulcers are principally designed to keep the peri-ulcer skin dry 
while maintaining a moist wound bed.  Topical antibiotics and antibacterials like silver 
sulfadizine, doxycycline or triple antibiotic are applied to cure or prevent infection. 21-22   
Debridement, irrigation, and warming are also employed to decrease bacterial load.  The 
healing of chronic wounds is further compromised by the failure of fibroblasts to produce 
adequate ECM proteins. 23    Various methods exist to balance proteases through 
implantation of cells, growth factors, hormones and other materials to secrete or enhance 
healing.   Wound pain management through use of analgesics and vitamin and mineral 
supplementation is also important in the resolution of chronic wounds.   Bromelain, 
vitamins A, C and E, zinc, and glucosamine are some of the supplemental vitamins and 
minerals used to promote wound healing.   
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2.2 Dendrimers for Drug Delivery 
Dendrimers are an inimitable class of polymeric nanoparticles that play key roles in 
emerging nanotechnology, biotechnology, and nanomedicine.  Dendrimers are spheroid or 
globular nanostructures that are precisely engineered to carry molecules encapsulated in 
their interior void spaces or attached to the surface. 24    Dendrimers are attractive in the 
field of nanomedicine as drug carriers for reasons such as: 
1. Low polydisperity index 
2. Multiple attachment sites  
3. A well-defined, controllable size  
4. A highly-branched globular structure that can be easily modified to change its   
chemical properties. 
 
5. Capability of drug encapsulation in the core of the dendrimer as well as 
dendrimer-drug conjugation by drug attachment to the surface of the dendrimer.  
 
The use of dendrimers for drug delivery and controlled drug release improves drug 
efficacy.  Controlling the release time and delivery location of therapeutic drugs allows 
sustained and targeted drug delivery in the therapeutically desirable range; thus 
contributing to lower drug dosages and a reduction of harmful side effects.     
2.2.1 Structure of PAMAM Dendrimers 
Dendrimers are large, complex macromolecules with well defined and consistent 
size and form.  Their highly branched, three-dimensional architecture consists of a core, 
branches and end groups.  Figure 2 is a schematic of a PAMAM (G2) dendrimer.  
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Figure 2: Chemical Structure of PAMAM (G2.0) Dendrimer    
 
 
 
 
 
Core 
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Surface group 
 
Size, shape, and reactivity of dendrimers are determined by generation (branch levels) and 
chemical composition of the core, interior branching, and surface functionalities. The 
terminal groups heavily influence the chemical properties of the molecule and physical 
properties such as solubility and viscosity. 25     Dendrimers with hydrophilic surface 
groups are soluble in polar solvents and vice-versa.  In solution, linear polymer chains 
exhibit flexible coils and dendrimers in comparison reflect a tightly coiled ball affecting 
their viscosity. 
 The multi-functionalized core of the dendrimer forms the central point of the 
molecule. The monomer chains that branch out from the core are termed the first 
generation, (G1.0); where the generation increases for every two monomer branches.  
Dendrimer surface area and size of the molecule increases with each generation- until the 
effect of steric hindrance prevents continued growth (branching).  Dendrimers become 
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densely packed as they extend out to the periphery forming a closed membrane-like 
structure.  At this juncture, dendrimers are said to have reached a critical branched state 
called the “starburst effect”. 25  The starburst effect is witnessed after the tenth generation 
for PAMAM dendrimers. 
 The shape of the dendrimer is determined by its generation.  Dendrimers of lower 
generations (G0-2) are asymmetrically shaped and contain more inner void space (internal 
cavities) as compared to higher generations.  Higher generation dendrimers (G4 and 
greater) are globular shaped. 26      
2.2.2 Synthesis of PAMAM Dendrimers 
Dendrimers are constructed through a set of repeating chemical synthesis 
procedures that build up from the molecular level to the nanoscale region.   Dendrimers are 
generally prepared using divergent or convergent methods.  Both methods involve iterative 
sequences in which each iteration leads to a higher generation dendrimer.  In the divergent 
method, the dendrimer grows outward from a multifunctional core.  The core reacts with 
monomers containing one reactive and two dormant groups giving rise to the first 
generation. 26   The dendrimer diameter increases linearly whereas the number of surface 
groups increases geometrically.   Disadvantages of the divergent method are side reactions 
and incomplete reactions of the end groups causing defects in the dendrimer structure.  
Additionally, the divergent method requires a large excess of reagents to drive reactions to 
completion and prevent side reactions.  This makes purification more difficult. 
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The convergent method resolves difficulties in the divergent method of dendrimer 
synthesis.  The convergent method sequentially builds the dendrimer from the end group 
inwards.  The method is initiated with the attachment of growing branched polymeric arms 
(dendrons) to a multifunctional core molecule.   Advantages of this approach include easy 
end-product purification and minimal defects.  The convergent method is limited in that 
steric problems occur in the reactions of the dendrons and core molecule.  26  
PAMAM dendrimers were the first dendrimers synthesized by Donald Tomalia and 
co-workers in the 1980’s. Ammonia  is used as the core molecule. 27   In the presence of 
methanol, ammonia reacts with methyl acrylate then ethylenediamine is added.    This 
allows ethylenediamine to also be used as a core molecule.  The free amino group at the 
end of each branch reacts with two methyl acrylate monomers and two ethylenediamine 
molecules to form successive generations.  Half-generation PAMAM dendrimers have 
tertiary anionic carboxylate groups; and for full generation have cationic amino terminal 
groups.   
2.2.3 Drug Delivery Mechanisms 
 Drug delivery systems are employed to increase the efficacy of therapeutic drugs 
through locally targeted and sustained release of a drug over time.  Two common drug 
delivery systems are liposomes and polymeric systems, yet both are limited.  Linear 
polymers are polydisperse; therefore the molecular weight distribution impacts in vivo 
biodegradation.  Liposome-based systems have poor stability and difficulty targeting 
specific tissues.   
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 Three main paradigms employed for dendrimer drug delivery are drug 
encapsulation, dendrimer-drug conjugation and lyposomes.   Encapsulation of drugs uses 
the steric bulk and internal cavities for entrapping hydrophobic drugs at the core.   
Dendrimer-drug conjugates are generated via covalent attachment to the dendrimer surface 
groups.  For example, dendritic unimolecular micelles can be fabricated through 
PEGylation on the dendrimer surface. 26-28   PEGylation stabilizes the entrapped drugs, 
provides additional sites to retain more drugs and increases the solubility of the entrapped 
drugs.   
 Regardless of the drug carrier design, the ideal drug delivery system should be 
inert, biocompatible, achieve high drug loading and increase solubility at physiological 
conditions.  The use of PAMAM dendrimers for the design of drug delivery systems is 
largely due to desired in vivo biological properties such as non-toxicity and non-
immunogenicity . 26 
2.3 Poly ( - hydroxy esters) 
Poly(-hydroxy esters) are the most commonly used synthetic polymers in tissue 
engineering applications. 29 As a biomaterial, poly (α-hydroxy esters) such as poly(-
caprolactone) (PCL) , poly(glycolic acid) (PGA) and the copolymer poly(lactic-co-glycolic 
acid) (PLGA), are desirable for their biocompatibility and biodegradation properties.    
Electrospinning the aforementioned synthetic polymers with natural polymers like 
collagen, gelatin, elastin, etc., increases the mechanical integrity and strength of the fibrous 
scaffold.  The biocompatibility of PGA, PLGA, and PCL copolymers, affirms their 
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preference as tissue engineered (TE) scaffold applications as they minimize the chronic 
foreign body reaction and facilitate tissue regeneration. 30    
The general selection criteria for the polymers used for this study was based on the 
mechanical properties and the time of degradation.  Key polymer properties are listed in 
Table 2.  Some of the benefits of the polymers used in this study are as follows:    
 Mechanical properties that  remain strong until surrounding tissue has healed.  
 Do not invoke an inflammatory or toxic response.  
 Metabolized in the body after fulfilling their purpose, leaving no trace.  
 Easy processing into final product form.  
Table 2: Polymer Properties 
Polymer Melting 
Point (°C) 
Glass-Transition 
Temp (°C)
Modulus 
(Gpa)a
Crystallinity  
(%) 
Degradation 
Time 
(months)b
PCL 58—63 (-65)— (-60) 0.4 30-70 >24
PGA 225—230 35—40 7.0 50 3 to 6
PLGA 85:15 
(ratio dependent)  
173—230 40—60 0.2 Amorphous 6 to 12
a) Tensile or flexural modulus.  b)  Time to complete mass loss.  
 
2.3.1 Poly(ε-caprolactone) (PCL) 
Poly(ε-caprolactone) is a biodegradable polyester prepared by ring opening 
polymerization of ε-caprolactone.  Because PCL is degraded by hydrolysis of its ester 
linkages in physiological conditions, it has received extensive interest for construction of 
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implantable biomaterials and drug delivery devices.  The ring-opening polymerization of -
caprolactone yields a semi-crystalline polymer with a melting point of 59—64°C and a 
glass-transition temperature of -60°C.   Biodegradation of PCL in vivo can take up to 30 
months. 31    Because the homopolymer has a degradation time greater than 2 years, 
copolymers have been synthesized to accelerate the rate of bioabsorption. PCL has been 
commercially developed as a resorbable suture, adhesion barrier, and used for TE 
scaffolds. 32   PCL beads are also used to encapsulate drugs for targeted and controlled drug 
release.      
2.3.2 Poly (glycolic acid)  (PGA) 
Poly(glycolic acid) is a biodegradable, thermoplastic polymer and the simplest 
linear, aliphatic polyester.  Poly(glycolic acid) is usually prepared by polycondensation or 
ring-opening polymerization. 33   Mostly soluble in highly fluorinated solvents like 
hexafluoroisopropanol (HFIP), high MW PGA polymer has been used in melt spinning, 
electrospinning and film preparation.  Poly(glycolic acid) undergoes hydrolytic 
degradation in physiological environments; which is augmented by enzymatic breakdown 
through esterase activity.  Poly(glycolic acid) degrades into glycolic acid, which is a 
naturally occurring byproduct in the metabolic pathway.  As such, glycolic acid is non 
toxic and excreted in urine and as water and carbon dioxide. 32    In vivo degradation of 
biomaterials synthesized with PGA is usually short; and degrades within seven days.  
Previous experimental studies of sutures made with PGA showed a 50% loss in material 
strength after two weeks; and complete loss of strength after four weeks. 34   
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One of the first biomedical applications for PGA was as a resorbable suture 
marketed in 1962 as Dexon™. 35   Because PGA yields strong fibers that degrade into 
water soluble monomers- it has found widespread use in surgical applications.  Implantable 
medical devices (e.g. rings, pins, rods, plates, screws, etc.) are also produced with PGA.  
The use of PGA as a biomaterial has evolved to fabrication of TE scaffolds and for 
controlled drug delivery.   
2.3.3 Poly (lactic-co-glycolic acid)  (PLGA) 
Poly(lactic-co-glycolic acid) is a copolymer synthesized by ring-opening co-
polymerization of two different monomers, the cyclic dimers (1,4-dioxane-2,5-diones) of 
glycolic acid and lactic acid. 36    Successive monomer units of glycolic acid and lactic acid 
are linked together via ester bonds to form PLGA during polymerization.   Different 
compositions of PLGA can be formed by altering the ratio of lactide to glycolide.  For 
example, PLGA 85:15 is comprised of 85% lactic acid and 15% glycolic acid.  PLGA can 
be dissolved by general solvents, such as tetrahydrofuran, acetone, chlorinated solvents 
and ethyl acetate. 37 
In the presence of water and in physiologic conditions, PLGA degrades by 
hydrolysis of its ester linkages.  The degradation rate is dependent on the monomer ratios.  
The more glycolic acid units present, the higher the polymer solubility thus resulting in 
faster degradation.   An exception to this rule is the copolymer with a 50:50 monomers' 
ratio, which exhibits the faster degradation (about two months). 37     
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The in vivo degradation of  PLGA yields the original monomers, lactic acid and 
glycolic acid.  Lactic acid and glycolic acid are by-products of various metabolic pathways 
in the body. 36   As a result, the use of PLGA for drug delivery and biomaterial applications 
causes minimal toxicity.    The ability to regulate polymer degradation rate by controlling 
the polymer monomer composition makes the use of PLGA in biomaterial applications 
highly appealing.  PLGA is used to construct various biomaterials like grafts, sutures, 
implants, prosthetic devices, and micro and nanoparticles.    
2.4  Wound Dressings 
Wound dressings play an essential role in the treatment and healing of chronic 
wounds.  Key functions of dressings for healing chronic wounds include: 
 
1. Protecting the ulcer from further injury,  
2. Preventing infection and invasion of bacteria and other germs, 
3. Maintaining the  proper environment for healing, 
4. Filling in the wound’s void space.  
 
Wound dressings, unlike gauze or bandages, aid normal healing by maintaining moisture 
in the wound bed.  A chronic wound has a better chance of healing when the moisture level 
is similar to that of healthy skin.    Wound dressings are classified based on their function 
in the wound, material type, physical form and contact layer level. 38   Categories are 
highlighted in Table 3.   
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Table 3: Various Categories to Classify Dressing Type 
Category  Different Classes 
Wound Function debridement, antibacterial, occlusive, absorbent, adherence 
Material Type hydrocolloid, alginate, collagen, hydrogel, etc. 
Physical Form ointment, film, foam, gelatin 
Contact Layer 
primary dressing (direct wound contact), secondary dressing 
(cover primary dressing),  island dressing (have a central 
absorbent region surrounded by an adhesive portion)  
2.4.1 Traditional and Emerging Dressings 
Wound dressings have evolved over the years from mere coverings (plant herbs, 
cotton wool, bandages and gauze) to bioactive, tissue-engineered (TE) scaffolds that 
dispense therapeutic agents in a controlled manner and facilitate tissue regeneration via 
interaction with cells.    Disadvantages of conventional dressings (e.g. cotton wool, gauze) 
for treating chronic (open) wounds include delayed wound healing and generation of more 
damage. 39   Gauzes are mainly used in chronic wounds as packing stuff to absorb fluid and 
exudates; thus drawing fluid away from the wound.  Some of the major disadvantages of 
using traditional dressings for chronic wound management include: 
1. Loss of bacterial protection when the outer surface of the gauze dressing 
becomes moistened by wound exudates or external fluids. 
2. Adherence of the dressing to the wound as fluids decrease.  The dressing 
becomes painful to remove and dries out the wound. 
3. Requirement of frequent change out which diminishes patient compliance. 
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Contemporary dressings have been developed to address the shortfalls of traditional 
dressings.  One of the most widely used dressings for chronic wounds are hydrocolloids. 38   
They are designed to be used for light to moderately exuding wounds such as pressure 
sores, leg ulcers, minor burns and traumatic injuries.  Hydrocolloid dressings are 
impermeable to water vapor in their intact state.  However, upon absorption of wound 
exudates, the physical state of the dressing transforms to a gelatin.   As the gelatin forms, it 
becomes more permeable to water and air. 40   The gelatin is not painful to remove, thus 
contributing to its popularity as a pediatric dressing.   Table 4 summarizes the top 
dressings used to treat chronic wounds, as well as some of the advantages and 
disadvantages of each. 41 
A new generation of bioactive and medicated wound dressings that mediate and 
regulate cell interaction are currently being developed, which is the focus of this study.  
This milestone evolution advances the following in wound care management: 
1. The fabrication of wound dressings from natural or biodegradable synthetic 
polymers (collagen, gelatin, chitosan, PGA, PLGA, PCL) that mimic the tissue 
matrix thus promoting cell attachment and proliferation. 
2. The application of medicated TE scaffolds that yield targeted and controlled 
release of antibiotics, antimicrobials, vitamin and mineral supplements and 
growth factors that accelerate wound healing. 
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Table 4: Different Dressings for Chronic Wound Management 
Dressing  Advantages Disadvantages 
Hydrocolloids 
 (light to moderate exudates) 
 
 
Impermeable to bacteria 
Can be left in place for up to 7 
days without changing 
Gelatin creates moist wound 
bed 
Impermeable to oxygen 
Cannot handle heavily 
exudating wounds  
Gel & smell phenomenon 
Hydrogels 
(dry and painful wounds) 
 
 
Soothing to patient 
Maintains intimate contact 
with the wound surface 
Creates moist environment for 
cell migration 
Need frequent changing 
Heavily exudating wounds 
causes  leakage  
Cost 
Alginates 
(moderate to heavy 
exudates) 
 
Highly absorbent 
Readily biodegradable; form 
gelatin upon exudates 
absorption 
Impermeable to bacteria 
Fibrous debris, lateral wicking 
Requires moisture to function; 
thus cannot be used for dry 
wounds 
 
Foams 
(light to moderate exudates) 
 
 
Absorbent 
Occlusive 
Thermal insulation 
Change every 3 days 
Smelly, malodorous discharge 
Opaque 
 
 
 
2.4.2 Electrospun Gelatin/Dendrimer Hybrid with Doxycycline 
Natural and synthetic polymeric wound dressings not only cover and protect the 
wound from bacteria and further damage, they can also serve as drug delivery systems and 
bioactive platforms to facilitate tissue growth.  Upon hydration by the wound exudates, 
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drug delivery is achieved via hydrolysis, diffusion or gelatin formation and release 
followed by degradation of the dressing/erosion of the gelatin.   The localized and 
controlled release of antibiotics is preferred over systemic delivery as it allows direct 
targeting of the wounded area and metered drug administration over an extended period of 
time. 
Doxycyline has been selected as the antibiotic to include in this study.  It is an 
effective antibiotic that has the ability to inhibit the degradative enzyme, MMP. 6  
Doxycycline is a member of the tetracycline antibiotics group, commonly used to treat 
infections.   Tetracyclines work by inhibiting protein synthesis in bacteria by binding to the 
30S ribosome, immobilizing the progressive translation of proteins thus preventing 
reproduction.   It is hoped that this mechanism of action will mitigate the formation of 
biofilms that routinely develop in chronic wounds.   Doxycycline is frequently used to treat 
inflammation of the prostate, respiratory and urinary tract infections, syphilis, pelvic 
inflammatory disease, acne and Lyme disease.42  It is also used to prevent and treat 
infections from E. Coli and methicillan-resistant Staphyloccus aureas (MRSA).   
Tissue-engineered scaffolds are used to direct the growth of cells that are either 
seeded within the porous structure of the scaffold or migrating from surrounding tissue.  43  
The regeneration of tissue, i.e. wound healing, can also be supported by growth factors and 
supplements that are contained in the dressing.  Electrospinning is recognized as an 
efficient processing method to manufacture TE scaffolds that mimic native ECM. 44   The 
originality of the proposed wound dressing is based on combining these technologies to 
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design an electrospun gelatin/dendrimer hybrid for the treatment of chronic ulcers. 
Uniqueness of the proposed dressing includes: 
1. Fabrication of an electrospun drug delivery platform made from the natural 
biopolymer gelatin (denatured collagen). 
2. Nano-electrospinning gelatin with copolymers PGA, PLGA, and PCL to 
enhance mechanical strength and ensure biodegradability. 
3. Controlled and targeted drug release of Doxycycline that facilitates wound 
healing as an antibiotic and by inhibiting the degradative enzyme,MMP. 
The advantages and disadvantages of the proposed dressing compared to dressings 
currently on the market are summarized in Table 5. 
Table 5: Proposed versus Contemporary Wound Dressings 41 
DRESSING ADVANTAGES DISADVANTAGES 
Foams  Highly absorbent 
 Debrides wound 
 Comfortable & conformable 
 Requires secondary dressing 
 Cost 
 Cannot be used on dry wounds
Hydrogels  Soothing to patient 
 Intimate contact with wound 
surface 
 Creates moist environment for 
cell migration 
 Need frequent changing 
 Cost    
 Cannot handle heavily 
exudating wounds without 
leakage 
Hydrocolloids  Impermeable to bacteria 
 Can be left in place for 
extended periods of time  
 Gel creates moist wound  
 Impermeable to oxygen 
 Cannot handle heavily 
exudating wounds   
 Gel & smell phenomenon  
Proposed  
Dressing 
 Controlled release of 
therapeutic drugs  
 Inhibition of destructive 
enzymes (MMP) 
 Maintains moist wound bed 
 Pure electrospun gelatin  is 
mechanically weak 
 Required to cross-link or 
electrospin with stabilizing 
polymers (PCL, PGA, PLGA) 
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CHAPTER 3 Experimental Materials and Methods 
 
3.1 Materials 
Table 6: List of Materials 
 
Material      Abbreviation 
 
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
4-dimethylaminopyridine 
4-nitro phenyl chloroformate 
Chloroform 
De-Ionized Water 
Deuterium oxide 
Dichloromethane 
Dimethylformamide 
Doxycycline 
Ethanol (denatured) 
Ethyl ether (anhydrous) 
Hexafluoroisopropanol 
Hydrochloric Acid 
N,N-Dicyclohexylcarbodiimide 
N-Hydroxy Succinimide 
Ninhydrin 
Poly (Glycolic Acid)   
Poly (Lactic-Co-Glycolic Acid)  (85:15) 
Poly(ε-Caprolactone) 
Porcine type-A gelatin 
Sodium carbonate 
Starburst™ G3.5 PAMAM dendrimer  
Tetrahydrofluran  
Triethylamine 
 
EDC 
DMAP 
NPC 
 
DI water 
D2O 
DCM 
DMF 
DC 
 
 
HFIP 
HCl 
DCC 
NHS 
 
PGA 
PLGA 
PCL 
Gelatin 
NaHCO3 
G3.5 
THF 
TEA 
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3.2 Equipment 
 
Table 7:  List of Equipment  
Name Purpose 
MTS Bionix 200®                   
Mechanical Testing System 
Measure the tensile properties (stress, elongation) of 
electrospun fibers. 
Scanning Electron Microscope     
Model 550 
Photographs of scaffolds (characterize morphology and 
fiber diameter using ImageTool™). 
Eppendorf Centrifuge Model: 
5415D 
For Centrifugation, separation of the suspended phase 
form liquid phase. 
Freeze Dry System – Labconco 
Model 77550 
Freeze dry system to dry the frozen samples. 
Nuclear Magnetic Resonance 
(NMR) 
Proton NMR measurement was performed on a 300 
MHz NMR spectrometer. 
Permeability Test Mechanism Designed and fabricated by Scott Sell to measure 
permeability (see section 3.4.6). 
Ultra Violet – Visible (UV-Vis) 
Spectrophotometer Genesys 6 
Quantitative analytical tool for Ninhydrin assay and 
release experiments. 
UV Radiation source UV light source, 90 W high-pressure mercury vapor 
filled lamp, manufactured by Phillips (Holland). 
Weighing Balance For measuring the required amount of materials. 
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3.3 Synthesis  
3.3.1 Conjugation of Gelatin to PAMAM Dendrimer G3.5 
The reaction synthesis for conjugating PAMAM G3.5 to gelatin is represented in 
Figure 3.  The reaction was carried out in three phases:  formulate the gelatin solution, 
activate the terminal carboxyl groups of the dendrimer and lastly, conjugate dendrimer to 
gelatin.    The gelatin solution was prepared by weighing and adding 20 mg of gelatin (type 
A Porcine powder) to 20 mL of sodium carbonate (pH 8.5).  The mixture was stirred at 
80°C until the solution was clear.   
Figure 3: Conjugation Reaction of Gelatin to G3.5 Dendrimer 
 
 
 
 
 
 
 
 
 
Conjugation of gelatin to G3.5 involved the activation of the carboxyl (-COOH) 
groups of the dendrimer using EDC chemistry to form a stable amide bond. Prior to the 
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water; added in 1mL increments and vortexed to ensure complete removal of PAMAM 
G3.5 from the evaporator flask and transferred to a scintillation vial.  PAMAM G3.5 has 
64 carboxyl surface groups (S.G.). 45   The EDC reagent was kept at a minimum to only 
activate half (32) of the surface groups.    The remaining surface groups were reserved for 
subsequent drug attachment.    To this solution, 3mg of NHS and 5mg of EDC were added 
and then stirred for 24hr at room temperature for activation of the surface groups.  The 
activated G3.5 solution was mixed with the gelatin solution and stirred in an ice bath for 4 
hr.  The salt was removed by centrifugation.  The supernatant obtained was then added 
drop-wise to 50 mL of cold ether and kept at -8 ºC for 24 hrs. The precipitate was collected 
and then dried via rotary evaporation.    Rapid dialysis (12-14000 MWCO dialysis tubing; 
DI water as the filtrate) was carried out to remove un-reacted NHS and EDC for 
purification of the product. The recovered product was lyophilized for 24 hr to dry the 
sample and then weighed.   
 
3.3.2 Conjugation of Doxycycline to PAMAM Dendrimer G3.5 
Conjugation of DC to PAMAM G3.5 involved the activation of carboxyl  (-COOH) 
groups of the dendrimer using HCl. Prior to the reaction, 0.75μmol of PAMAM G3.5 was 
dried via rotary evaporation. The obtained dry product was then dissolved in 1 ml of DI 
water. The solution was acidified with three to four drops of 1 N HCl (pH=1.0). The 
acidified solution was dried again by rotary evaporation and then re-dissolved in 2 ml of 
DMF (added at 1mL increments, vortexed and transferred to a scintillation vial). To this 
solution,  15mg of DC, 8.5mg of DCC and 3.4mg of DMAP were added.  The solution was 
 
 
26 
CH3
stirred for 14 hrs at 4 ºC in an ice bath. After stirring, the solution was added drop wise to 
40 mL of cold ether and kept at -40 ºC for 24 hrs to precipitate the salt (DCU). The mixture 
was centrifuged to remove the precipitate. The supernatant was dried by means of rotary 
evaporation.  After drying, dialysis- with DI H2O as the filtrate, was performed to remove 
non-reacted DCC and DMAP for further purification of the product. The recovered 
product, G3.5 conjugated to DC, was analyzed by 1H-NMR.  We could not confirm the 
synthesis of DC to PAMAM G3.5.  As this reaction did not yield the desired result, DC 
was encapsulated in the spinning solutions and electrospun into a gelatin/dendrimer hybrid.  
 
Figure 4: Proposed Conjugation Reaction of DC to G3.5 dendrimer 
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3.3.3 Encapsulation of Doxycycline 
Twenty milligrams of DC powder and 10 mg of PAMAM G3.5 were measured and 
dissolved in 5mL of HFP along with various weight ratios of gelatin and the polymers 
included in this study.  It was assumed that as the melt polymer solutions were ensured to 
be homogenous prior to electrospinning, that DC and PAMAM G3.5 would also be evenly 
distributed with the other contents (gelatin and synthetic polymers) in the electrospun mat.   
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3.3.4 Polymer-Gelatin Spin Dope Solutions 
Solutions of 100 wt % gelatin, 50/50 (w/w) and 70/30 (w/w) PCL/gelatin, 50/50 
(w/w) and 70/30 (w/w) PGA/gelatin and 50/50 (w/w) and 70/30 (w/w) PLGA/gelatin were 
prepared by dissolving 500mg total in 5mL of HFIP in a glass scintillation vial.  All 
reagents were purchased from Sigma Aldrich Corporation and the synthetic polymers were 
purchased from Lakeshore Biomaterials.  Solutions were mixed for 24h on a shaker plate 
to ensure complete dissolution to form a homogenous solution.  The solutions were loaded 
into a 5 mL Beckton Dickinson syringe and placed in a KD Scientific syringe pump 
(Model 100) for electrospinning. 
3.3.5 Electrospinning  
Electrospinning is a type of extrusion type fiber fabrication method that employs 
the use of an electrical charge to product micro and nano-scaled fibers from a liquid.   The 
experimental setup used for the electrospinning process is schematically shown in Figure 
5.    To form fibers during electrospinning, a polymer solution is loaded into a syringe and 
forced to the needle tip by a syringe pump.   A positively charged electrode is attached to 
the needle and when voltage is applied, a static electric field is created causing the droplet 
of polymer at the end of the syringe to be stretched into a conical shape known as the 
Taylor cone. With increasing electrical field, the discharged polymer solution jet is 
elongated and whipped continuously by electrostatic repulsion causing the solvent to 
evaporate.   The charged polymer fiber is deposited on a grounded collector.    For this 
study, an adjustable high voltage power supply (Spellman CZE1000R; Spellman High 
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Voltage Electronics Corporation) was used to apply a 25kV voltage to a blunt tip 18 gauge 
needle fixed to the solution containing syringe.  The negative electrode was connected to a 
metallic lab rack with its circular plateau wrapped in aluminum foil.  The spin solution was 
delivered via a syringe pump controlling the mass flow rate to 3.5 mL/hr.  Solutions were 
electrospun onto a flat, stainless steel, grounded mandrel (2.5 x 10.2 x 0.3 cm) placed 
approximately 12 cm from the needle tip and rotated at 500 rpms with back and forth 
traversing to produce a scaffold of randomly oriented fibers; evenly distributed along the 
collector mandrel.  Upon completion of the spinning process, the scaffolds were removed 
from the mandrel (sides slit; then gently peeled); and placed in the fume hood for 
degassing and removal of HFIP.  Samples were then stored for 24h in the dessiccator to 
ensure moisture removal. 
Figure 5: General Electrospinning Apparatus  
Metering Pump
 
 
 
 
 
 
3.4 Characterization  
3.4.1 Ninhydrin Assay 
Verification of the conjugation of gelatin to G3.5 was indirectly determined by 
measuring the remaining amine surface groups of gelatin with the ninhydrin assay. The 
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ninhydrin stock solution was prepared by dissolving 70 mg of ninhydrin in 20 mL of 
ethanol. Gelatin-G3.5 conjugates in very small amounts (1 or 2 mg) were dissolved in 1 
mL of ethanol and further mixed with 1 mL of ninhydrin stock solution. The mixture 
solution was heated to 90 °C for 5 minutes after which it was cooled down to 25ºC. The 
concentration of amine groups ( [NH2], mg/mL) was determined at the wavelength of 570 
nm based on the calibration curve, which was established using pure gelatin of known 
concentrations.   The standard curve for gelatin in ninhydrin is graphed in Figure 6. 
Figure 6: Standard Calibration Curve of Gelatin (Ninhydrin Assay) 
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3.4.2 1H-NMR Spectroscopy 
1H-NMR spectra of the synthesized polymers were recorded on a Varian 
superconducting Fourier-transform NMR spectrometer (Inova-400). Deuterium oxide 
(D2O, 99.9%) was used as the solvent. The chemical shift for D2O is 4.8 ppm. Post- 
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processing was done using “Spin-Works” (free shareware) software courtesy of the 
University of Manitoba, Canada.  
3.4.3 Mechanical Property Testing 
Dog bone-shaped samples were cut (1.85 cm-length x 0.6 cm-outer diameter x 0.3 
cm inner diameter) with a punch die for mechanical testing.  The punch was positioned on 
the electrospun mat perpendicular to the mandrel’s axis of rotation.  Six dogbones were cut 
from each mat and the sample thickness measured using digital calipers.  Uniaxial tests 
were conducted using a Bionix 200 Mechanical Testing Systems with a 50N load cell.  The 
offset edges of the dog bone specimen were loaded into the metal grips of the machine and 
tested at 10 mm/min until failure.  Stress, strain, elastic modulus, peak load, and break 
were calculated and reported from the TestWorks4 computer software program.     
3.4.4 Scanning Electron Microscopy (SEM)  
Fiber morphology and fiber diameter were observed under scanning electron 
microscopy (SEM) employing a JEOL JSM-820 JE electron microscope with an 
acceleration voltage of 15kV.  Samples were cut from each scaffold and gold sputter 
coated (Model 550; Electron Microscope Sciences) in preparation for scanning electron 
microscopy.  An SEM photograph of each sample was taken at 1700x magnification.  
Thirty different fibers were measured using ImageTool 3.0 image visualization software 
(shareware provided by UTHSCSA).   The software was calibrated using the micron scale 
bar of each photograph and average fiber diameter reported.   
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3.4.5 Porosity Measurement 
Porosity, expressed as the percentage of void to total volume, was determined using 
the apparent volume method.   The following equation was used to calculate porosity: 
 100)](1[ 
a
g
V
VP       Equation 1  
Where: Vg = mass of the scaffold / density of collagen (1.41 g/cm3) 
 Va = apparent volume of square section 1cm x 1cm x thickness 
Sample thickness was measured using digital calipers.  Three samples from each specimen 
were used to determine the porosity of each scaffold. 
3.4.6 Permeability Measurements  
The permeability of three punches (12 mm diameter) from each electrospun mat of 
each blend was measured using a meter developed by Scott Sell based on Ogston’s theory 
of flow through systems of long thin rods.46   Water was the fluid utilized for testing the 
samples.   Permeability, represented as the Darcy constant (τ), is calculated using the 
following equation: 
tAp
DQ      Equation 2     
where: Q=volume flowing through system,  =fluid viscosity (0.89 cP),  
D=scaffold diameter (12 mm),  A=cross-sectional area of scaffold ( r2),  
p=applied pressure (i.e. gh= 1000 kg/m2 * 9.8m/s2* 1.5m(h); converted to 
atmospheres).      t = time in seconds 
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Pore size was calculated by using the permeability determined in Equation 2 and the 
formula:     
    5093.0r     Equation 3  46 
 
 
3.4.7 Absorption and Water Swelling Behavior  
The swelling ratio was used to evaluate the absorption properties of each dressing 
type.  The swelling ratio of each test membrane was determined by immersing the sample 
in phosphate-buffered saline (PBS, pH 7.4) at room temperature. Subsequently, the weight 
of the swollen membrane was determined by sandwiching the membrane between two 
paper towels to remove excess water on the surface and weighed immediately. The 
swelling ratio (Rsw) of each test sample in PBS was calculated as follows: 
 
100])([ 
i
if
SW
W
WWR   Equation 4  
where: Wf denotes the weight of the test sample after swelling and Wi is its initial weight.  
Three samples per gelatin-polymer blend were evaluated to determine water swelling 
kinetics.   
 
 
33 
 3.4.8     In vitro Degradation 
The in vitro degradability of each test sample was assessed as a measure of 
physiologic degradation. The test samples were well immersed in PBS (pH 7.4) and 
incubated at 37°C for 24h.  After degradation, the test samples were centrifuged for 20 min 
in deionized water, frozen, then lyophilized for 5 h and weighed. The ratio of weight loss 
(RWL) due to in vitro degradation for each test sample was calculated using the formula: 
100])([ 
i
fi
W
WWRWL    Equation 5 
where Wf denotes the weight of the test sample after in vitro degradation and Wi is its 
initial weight.  Three samples per gelatin-polymer blend were evaluated for this analysis.    
Additionally, degradation was evaluated for 7 days by the above method; to evaluate 
degradation rate for each hybrid. 
 
3.4.9   Drug Release Kinetics of Doxycycline 
Drug release kinetics were determined through dialysis of the drug in DI water.   
Figure 7: Analytical Set-up for Drug Release Kinetics    
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To study drug release kinetics, samples of each electrospun gelatin-polymer mat 
were obtained, weighed and loaded into a dialysis tube.  After the tubing was clamped at 
one end,  20mL of PBS (pH 7.4) was added.    At least 50% of the total scaffold weight 
was utilized and the remainder of the sample retained for replicate testing (to evaluate 
accuracy and reproducibility).    The filtrate, 400mL of DI water, was added to three 
separate beakers and heated to 37 °C.  After heating to the set-point, the sample (dialysis 
diskette) was immersed in each beaker.  The 50/50 w/w gelatin-polymer blends were 
evaluated at the same time, but in 3 different beakers.  The 70/30 w/w gelatin-polymer 
blends were tested in the same manner.    To evaluate the short-term drug release, samples 
were collected at the following time intervals (in minutes):  2, 5, 7, 10, 15, 25, 35, 45, 60, 
75, 90,120, 150, 180 and 240 for 15 samples.  The absorbance value was recorded from the 
UV-Vis spectrometer for each sample per hybrid at the cut-off wavelength of 190 nm.  
After each measurement, the sample was re-injected into the beaker to keep the level of 
filtrate constant.  The observed absorbance value was referenced against the standard curve 
of DC and the concentration of the drug was interpolated.   Doxycycline was dissolved in 
DI water at a concentration of  1 g/mL and scanned for the maximum absorbance on the 
UV-Vis spectrometer.  Figure 8 shows that the maximum absorbance for DC is at a cut-off 
wavelength of 190 nm.  The standard curve of DC was developed using a cut-off 
wavelength of 190 nm and is shown in Figure 9.  The initial amount of DC was calculated 
from the ratio of the sample weight divided by total scaffold weight equal to unknown DC 
initial weight divided by total DC.  The initial drug weight ranged from 2 to 5 mg per 
sample.   
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Figure 8:  UV-Vis Scan of DC  ( 1 g/mL)  
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Figure 9: Standard Calibration Curve of DC (190 nm)   
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Drug release over time was determined by calculating percent drug release. The 
percentage of drug release was calculated as follows: 
100)(% 
i
t
C
CDR          Equation 6 
where Ct= concentration of drug released at time (t), and Ci = initial concentration of drug 
in the sample.  Initial drug concentration was calculated from the ratio of specimen weight 
divided by total sample weight equal to the mass of DC divided by the total DC added to 
the electrospinning solution.  Initial concentration of DC per test specimen ranged from 
0.04 to 0.05 mg/mL. 
 
3.4.10   Statistical Analyses and Graphical Representations 
Minitab Statistical analysis software was utilized to perform Analysis of Variance 
(ANOVA), Analysis of Means (ANOM) and Tukey’s Test for Significance to determine 
statistical differences (if any) between fiber diameter and the mechanical properties of peak 
stress, modulus and breaking strain across different blend compositions and w/w ratios.  
Analysis of variance is a statistical test that compares the variation within a group to the 
variation among groups. A positive ANOVA indicates that the differences among groups 
are more substantial than would be expected by chance alone. Analysis of means is a 
graphical analog used for testing the equality of population means.  MINITAB displays a 
graph, similar to a control chart, highlighting group means that are different from the 
overall mean.  If differences among the sample groups were found, Tukey’s pair-wise 
comparisons were done to determine which values were significantly different. Tukey’s 
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method compares the means for each pair of group levels using an overall error rate that is 
specified by the user.  Results are presented as confidence intervals for the difference 
between pairs of means.  If an interval does not contain zero, the means are statistically 
different, else accept the null hypothesis (means are the same).  An alpha level of 0.05 was 
selected for all statistical tests. Graphical representations were constructed using Microsoft 
Excel 2003 and MINITAB. 
 
 
 
38 
CHAPTER 4 Results and Discussion 
 
4.1 Preparation and Characterization of G3.5-Gelatin Conjugates 
EDC chemistry was used to conjugate gelatin to PAMAM G3.5 dendrimer (Figure 
10).  A UV-Vis spectrophotometer scan of pure gelatin and PAMAM G3.5 yielded 
overlapping peaks; which negates this analytical tool from confirming the synthesis.  
Subsequently, verification of the conjugation of gelatin to G3.5 was indirectly determined 
by measuring the remaining amine surface groups of gelatin with the Ninhydrin assay.  
Ninhydrin reagent reacts with amino acids resulting in a purple colored solution.47   The 
absorbance can be measured at the 570 nm wavelength on a UV-Vis spectrophotometer.  
Per the standard curve for gelatin with ninhydrin reagent (Figure 3), a 1 mg/mL sample of 
gelatin would have an absorbance value of approximately 0.1685.   Ninhydrin reagent 
solution was added to a 1 mg/mL sample of the G3.5-gelatin conjugate; measured at 570 
nm on the UV-Vis.   The measured low absorbance value of 0.027 resulted from the 
decrease of  the terminal amine groups –NH2 of the gelatin due to the coupling reaction. 
 
Figure 10: Schematic of Reaction to Form an Amide Bond 48 
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The Steglich esterification method of forming esters under mild conditions was 
attempted to conjugate PAMAM G3.5 dendrimer to doxycycline (Figure 11).  Steglich 
esterification involves activating the carboxylic (-COOH) groups of the dendrimer with 
DCC.  After activation, DMAP is used as a catalyst. We were not successful in conjugating 
DC to PAMAM G3.5.  The hydroxyl groups of the DC were inaccessible; and could not be 
used to form an ester bond with the carboxyl groups of the dendrimer  
Figure 11: Schematic of Steglich Esterification to Form an Ester Bond 49 
 
The conjugation of G3.5 to DC was not confirmed by 1H-NMR as shown in Figure 12 
below.  The peak for DC was not evident in the NMR image. 
Figure 12: 1H -NMR of DC-PAMAM G3.5 
 
The yield of the G3.5-DC reaction synthesis ranged from 35 to 45% in five replicates of 
the reaction steps.  Low yield can be attributed to product purification through dialysis.  
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The dialysis tubing used in the purification process had a molecular weight cut-off 
(MWCO) of 12000-14000.  Doxycycline is small enough to escape through the pores.  Due 
to the poor yield of this reaction and inadequate reproducibility, other therapeutic drugs are 
being explored in our laboratory.   Because we were not successful in the synthesis of 
conjugating PAMAM G3.5 to DC, the drug release kinetics from the electrospun wound 
dressings will be performed using encapsulation of DC in the spinning solution.  
Two different PAMAM dendrimers, G3.5 and G4, were electrospun with gelatin to 
evaluate scaffold morphology and mechanical properties.  Three different concentrations 
of dendrimer in gelatin were electrospun and evaluated.  The G4 dendrimer/gelatin mats 
showed significantly larger fiber diameters, with means ranging from 3.4 to 4.2 m. and 
displayed a flattened and oblong cross-section.  The G3.5 dendrimer /gelatin mats had 
smaller diameter fibers, ranging from 1.8 to 2.5 m on average.  The G3.5 
dendrimer/gelatin hybrids exhibited a cross-section similar to pure electrospun collagen 
and gelatin.  The full generation PAMAM dendrimers have a positive charge; whereas the 
G3.5 dendrimers have a negative charge. These charge differences influence the electrical 
field during electrospinning, increasing the charge differential thereby altering the fiber 
diameter.  It is believed that solvent evaporates more readily from the positively charged 
polymer solution, forming a skin layer on the exterior.  After the fiber is formed, the outer 
skin collapses forming an elongated, oval cross-section.  These data are shown in Figures 
13 and 14.  Electrospun scaffolds containing PAMAM G3.5 dendrimer had the desired 
morphology and fiber diameter to resemble native ECM and will be further evaluated.   
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Figure 13: SEM of PAMAM G3.5 and G4.0 Scaffolds 
 
G3.5A:4mg, G3.5B:6mg, G3.5C:10 mg, G4.0A:4mg, G4.0B:6mg, G4.0C:10 mg, 
scale bar = 3 m  
 
G3.5A 
G3.5A 
G4.0A 
G3.5B G4.0B 
G3.5C G4.0C 
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Figure 14: Fiber Diameter of PAMAM G3.5 and G4.0 Scaffolds 
 
 
 
 
 
 
 
109876543210
G4.0C
G4.0B
G4.0A
G3.5C
G3.5B
G3.5A
FibrDiam
Ty
pe
4
3
4
3
2
2
Fiber Diameter by Dendrimer/Weight Percent
G3.5 vs G4.0
iber Diameter measured in micrometersF
An additional study was done to determine if DC drug encapsulation impacts 
spinnablity and fiber diameter.  Conjugates of G3.5 and gelatin, along with pure gelatin 
solution containing DC were mixed in solution with TFE and electrospun.  A comparison 
of means for strain, stress and Modulus are summarized in Table 9.    Mechanical strength, 
as measured by stress and strain, is significantly different for the scaffold mats of G3.5-
gelatin conjugates (at 0.10 MPa, 0.16 mm/mm) versus pure gelatin (at 1.40 MPa, 0.06 
mm/mm) or gelatin with encapsulated DC (at 0.96 MPa, 0.06 mm/mm).   The 
encapsulation of DC into the scaffold did not significantly impact mechanical properties.  
The statistical difference of significantly lower stress in the scaffolds with G3.5-gelatin 
conjugates is attributed to the smaller diameter fibers.50   Gelatin scaffolds are easily 
dissolved in aqueous environments.  Synthetic polymers were added to increase 
mechanical strength and reduce dissolution rates; and further characterize scaffolds. 
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Table 9: Mechanical Properties of Electrospun Gelatin 
 
Scaffold Strain (mm/mm) Stress, (MPa) Modulus, MPa 
Gelatin 0.06  0.01 1.400.58 37.59  16.09 
Gelatin+DC 0.06  0.02 0.960.52 26.09  10.44 
Gelatin-G3.5 0.16  0.04* 0.100.02* 1.13  0.21* 
 
Comparison of Means – Means with an asterisk (*) are statistically different 
                                        ( =0.05, Pr < 0.001)  
 
4.2 Gelatin/dendrimer Hybrid Morphology 
The SEM photographs were similar for all of the polymer gelatin blends; and 
similar to electrospun gelatin as shown in Figure 15.   Gelatin and the synthetic polymers 
were successfully electrospun into uniformly distributed fibrous scaffolds (Figure 16). All 
samples displayed homogenous fibrous structures when observed via SEM.   
Figure 15: SEM of Electrospun Gelatin 
 
 
 
 
 
 
  
Scale bar: 2 m, 1.05 kX magnification 
 
 44 
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Figure 16: SEM Micrographs of Polymer Blends  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A:50/50 PCL/gel,B:70/30 PCL/gel,C:50/50 PGA/gel,D:70/30 PGAgel,E:50/50 PLGAgel,F:70/30 PLGA gel 
Scale bars: A=10 m, B=3 m, C=10 m, D=10 m, E=10 m, F=2 m   
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The scaffold morphology, represented by fiber and pore diameter and visual 
observations, is similar to previously reported data of electrospun gelatin scaffolds.18,44   
The fiber diameter and mechanical properties are summarized in Table 10 and graphically 
represented in Figure 17.  Fiber diameters varied with the varying w/w ratio of gelatin to 
polymer and polymer type.  Much of the previously published electrospun data on gelatin 
show that increasing gelatin concentration increases fiber diameter.  Additionally, 
increasing fiber diameter causes an increase in mechanical strength.  50   
Table 10: Summary of Mechanical Properties.  
 Fiber Diameter 
( m) 
Stress  
(MPa)
Modulus 
(MPa)
Strain 
(mm/mm) 
Break 
Energy
(N-mm)
Gelatin 
(Control) 
2.2 ± 0.1 1.6 ± 0.3 22.1 ± 7.3 0.06 ± 0.02 0.11 ± 0.04
PCL/gel 
50/50 
2.0 ±  0.7 2.8 ± 0.8 41.9 ± 9.3 0.09 ± 0.02 0.32 ± 0.07
PCL/gel 
70/30 
1.9 ±  0.9 2.3 ± 0.6 19.0 ± 5.2 0.39 ± 0.09 1.06 ± 0.54
PGA/gel 
50/50 
1.7 ±  0.9 *0.7± 0.3 18.2 ± 9.7 0.06 ± 0.01 0.13 ± 0.07
PGA/gel 
70/30 
*2.7 ±  1.1 *3.7± 0.7 36.8 ± 13.9 *2.66 ± 0.35 *39.17 ±0.95
PLGA/gel 
50/50 
1.8  ±  0.8 0.6 ± 0.3 9.2 ± 6.4 0.16 ± 0.05 0.15 ± 0.05
PLGA/gel 
70/30 
*1.3 ±  0.8 *4.6 ± 1.0 *47.5 ± 13.8 *1.84± 0.30 *43.62 ±0.38
Statistically different means are marked (*) 
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Figure 17: Graphical Summary of Fiber Diameter, Stress, and Strain  
Gelatin/Polymer Dressing - Average Stress
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In this study, the gelatin concentration and synthetic polymer concentration were 
varied together.  Therefore, determining the impact of changes in gelatin concentration on 
the mechanical properties was confounded with the changes in synthetic polymer 
concentration and type. 
Fiber diameter of electrospun gelatin has been shown to be a function of solution 
concentration as concluded in our previous work.  With the exception of the PGA/gel 
70/30 blend (significantly larger fiber diameter) and PLGA/gel 70/30 blend (significantly 
smaller), fiber diameter was not statistically different.    Additionally, the inclusion of DC 
in the spin solution had no effect on pore area or fiber diameter when comparing the mat to 
100% gelatin as the control.     The mean fiber diameter ranged from 1.3 um to 2.7 um with 
a pooled standard deviation of 0.9 (Appendix A).   Statistical differences were analyzed 
using ANOVA in Minitab.  The fiber diameters for PGA/gel 50/50 blend were 
significantly smaller than the PGA 70/30 blend; however, the opposite was true in 
comparing PLGA/gel 50/50 and 70/30 w/w preparations.  The fiber diameter for the latter 
was significantly smaller.    Possible contributors are the change in synthetic polymer 
weight affecting the spin solution viscosity; thus impacting fiber diameter.    
The ANOVA and Tukey’s comparisons confirmed graphical observations of stress 
by type and w/w blend ratios.  Mean stress is statistically higher in the 70/30 PLGA/gel 
mat, which is significantly higher than the 70/30 PGA/gel blend; which is statistically 
higher than all other blends including the gel control.    The larger diameter fibers in the 
PGA/gel 70/30 blend is the main contributor the higher stress; as larger diameter fibers are 
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stronger in tension.   All variables of the fabrication process were controlled (i.e. the 
distance to mandrel, spinning voltage, mandrel rotation and geometry were held constant).  
Therefore the changes in fiber diameter and mechanical properties are solely due to the 
polymer type and weight ratios of gel to polymer.   
The mean strain for the study mats ranged from 0.05 to 2.66 mm/mm with a pooled 
standard deviation of 0.18 (Appendix).   The strain for PGA/gel 70/30 and PLGA 70/30 
blends were significantly different from the strains exhibited in the other blends, including 
the electrospun gel control, and each other.    This may be large due to similar physical and 
chemical properties of PGA and PLGA.   
Regardless of the mechanical property measured, the greater the percentage of 
synthetic polymers PGA and PLGA in the blend, the more extreme the values for stress 
and strain.  Both PGA and PLGA at the higher weight ratios showed greater mechanical 
strength, as measured by stress and break energy when compared to pure electrospun gel as 
the control.  This infers that the addition of PGA and PGLA will yield stronger electrospun 
mats.  One of the main reasons for blending and electrospinning the synthetic polymer with 
gelatin was to increase the mechanical strength and aqueous stability of the dressing.  The 
encapsulation of dendrimer and DC in the spinning solutions did not significantly impact 
the stress and strain properties of the scaffold.   
4.3 Porosity, Permeability and Swelling Behavior 
The electrospun polymer matrices were evaluated for fluid and gas flow capability 
to confirm their viability as a wound dressing.  The data is summarized in Table 9 and 
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graphically represented in Figures 18 through 21.  Fluid and gas exchange is essential to 
ensure adequate wound healing.  Cell migration, oxygen and moisture are essential to 
ensure tissue regeneration in chronic wounds.  The ultimate test to determine the success of 
the proposed dressing is dependent on its ability to mimic native ECM and allow cells to 
infiltrate the construct, migrate through its thickness and proliferate as ECM is essential to 
remodeling.51   Tissue regeneration is also facilitated by adequate nutrient flow, gas 
exchange and maintenance of a moist wound bed for proper healing. 52     Scaffold pore 
diameter, porosity, permeability and swelling and degradation behavior were evaluated as 
a means to measure its suitability and ability to ensure adequate flow of oxygen into the 
wound bed; while simultaneously maintaining a moist wound bed.   
Table 9: Summary of Gel-Polymer Matrix Fluid Flow Capability 
 Pore Diameter  
( m)* 
Porosity 
(%) 
Permeability 
(D)
RSwelling  
(%) 
RDegradation  
(%)
PCL/gel 
50/50 
0.28 ± 0.01 87.4 ± 0.2 0.0028 ± 0.0003 345.6 ± 10.7 28.3 ± 8.3
PCL/gel 
70/30 
0.25 ± 0.11 86.3 ± 1.0 0.0024 ± 0.0015 296.3 ±  8.6 10.6 ± 1.2
PGA/gel 
50/50 
0.31 ± 0.85 86.7 ± 0.7 0.0036 ± 0.0014 520.3 ± 41.3 30.4 ± 14.6 
PGA/gel 
70/30 
0.23 ± 0.04 82.9 ± 2.2 0.0024 ± 0.0008 294.6 ± 41.7 45.0 ±  7.1
PLGA/gel 
50/50 
0.39 ± 0.02 89.8 ± 1.8 0.0048 ± 0.0021 347.1 ± 34.9 10.0 ± 9.3
PLGA/gel 
70/30 
0.23 ± 0.39 85.2 ± 0.7 0.0024 ± 0.0007 256.7  ±  7.1 15.5 ± .2
Pore Diameter calculated from Equation 6 using permeability(*) 
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Porosity is a measure of the amount of void space in the electrospun scaffold and 
values are shown in Figure 18.   The porosity ranged from 83 to 89%.  The lowest porosity 
value was supported by SEM depictions of the 70/30 PGA/gel polymer blend.  The scan 
shows minimal pores; which is also confirmed by pore diameter as calculated by the Darcy 
permeability.  None-the- less, these levels are suitable as a TE construct as they are in the 
acceptable 70-90% range for adequate gas and nutrient exchange to underlying cells. 
Figure 18: Gel/Polymer Dressing - Porosity 
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Permeability is a measure of the ease of flow through a scaffold.   The permeability 
ranged from 0.0024 to 0.0048 Darcy.    The lowest porosity value was supported by SEM 
micrograph of the minimal pore diameter.  Permeability trended with porosity, in that the 
50/50 PLGA/gel mat was the most porous and showed significantly higher permeability.  
Permeability measurements are depicted in Figure 19. 
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Figure 19: Gel/Polymer Dressing - Permeability 
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 Water swelling results are presented in Figures 20 and 21.  The swelling rate was 
found to be a function of polymer type and weight ratio of each individual component of 
the gelatin/polymer hybrids.  For all the gel-polymer blends, the swelling rate showed a 
maximum value at the 30 minute time interval; thereafter reaching a plateau.   
The 50/50 PLGA/gel mat showed the highest porosity (openness) and the highest 
permeability (ease of flow), as the two are interrelated.  As expected, the least amount of 
swelling of the fibers occurred in this mat as a result of the increased void space, where 
fibers are non-existent.  Likewise, the 70/30 PLGA/gel mat was one of the least porous 
structures and thus had the highest swelling rate for the two hour evaluation.  The swelling 
ratios were higher for the 50/50 w/w versus 70/30 w/w blends, which is a result of the 
swelling behavior of the gelatin.    These data are shown in Figures 18 and 19. 
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Figure 20: Gel/Polymer Dressing – Swelling Rate 
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Figure 21: Gel/Polymer Dressing – Swelling Behavior 
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The synthetic polymers used in this study, PCL, PGA and PLGA, are susceptible to 
hydrolysis at various rates.  The rate and extent of hydrolysis is heavily dependent on the 
hydrophilicity of the individual  polymer and any co-polymers.  The more hydrophilic the 
polymer, the more aggressive the hydrolysis will be. 53     The blending of the synthetic 
polymers with gelatin as a co-polymer impacts the hydrophilicity of the electrospun 
polymer matrix and their electrospinning conditions since intrinsic viscosity changes.    
Subsequently, the degradation rates will also be impacted.  Based on the physical and 
chemical properties of the synthetic polymers evaluated in this study, PGA should have the 
faster rate of swelling, as it is the most hydrophilic of the three.   Figure 22 is a depiction 
of the bulk degradation sequence for the synthetic polymers used in this study.   
Figure 22: Theoretical Bulk Degradation Sequence   
 
PGA
2- 4 weeks--------------- 6 months-----------------------12 months                 > 2 years
PCLPLGA
 
 
 
In our evaluation, the 50/50 gelatin/polymer blends degraded at a much faster rate.  This is 
mostly due to the higher amount of gelatin; thus faster hydrolysis in comparison to the 
higher amouNt of synthetic polymer.  The synthetic polymer blends with PCL showed the 
least amount of degradation, as PCL can take up to 2 years to degrade in-vivo.  Regardless 
of the blend ratio, PLGA degraded at a significantly higher rate than the other two 
polymers (PCL and PGA); which did not follow the theoretical prediction.  The 24-hour 
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degradation is shown in Figure 23.  Note that the scaffold with the highest permeability 
and porosity, showed the fastest degradation.   
Figure 23: Gel/Polymer Dressing – Degradation 
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The degradation results were not consistent with the water swelling results, but 
were consistent with the observed trend for permeability.  Bulk degradation, considered 
homogenous hydrolysis, occurs when the diffusion of water into the polymer matrix is 
faster than the overall rate of hydrolysis.54    As water diffuses into the matrix and cleaves 
the ester bonds, erosion of the fibers occurs leading to a decrease in mass.  For PLGA, the 
degradation time is dependent on the monomer ratio of lactide to glycolide.  The more 
glycolide monomers, the more hydrophilic the co-polymer.  PLGA 85:15 is less 
hydrophilic than PGA and should have degraded at a slower rate.  However, the higher 
porosity and permeability in the PLGA/gelatin 50/50 w/w electrospun mat is credited as a 
major contributor to the faster degradation, since degradation rate is also dependent on the 
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morphology, porosity and permeability.  Degree of crystallinity also affects degradation.  
The greater the degree of crystallinity, the slower the degradation.  Poly (lactic-co-
glycolic) acid is amorphous which results in a faster in vitro degradation rate. 
4.4 Drug Release Kinetics 
It has been shown that the release of active drugs as function of time can be 
measured by means of diffusion of the drug from a porous membrane.  Diffusion 
controlled drug release was achieved by using dialysis tubing loading with the sample, 
containing the drug and PBS as the dialysate.  Doxycycline was measured when the drug 
diffused from higher concentration (inside the porous membrane) to the filtrate, which in 
our study was deionized water.  Figure 24 is a graphical representation of the drug release 
of DC over time.  We observed that an increase in the weight of the synthetic polymer 
resulted in the lower amount of released drug.    In both ratios, regardless of polymer type, 
controlled release of the drug is apparent.  The release, however is short-lived, reaching a 
plateau within two hours, with no significant release thereafter.   We hypothesize that the 
plateau is due to hydration of the gelatin and synthetic polymers causing the fibers to 
swell, thus increasing their fiber diameters and subsequently reducing pore size.  The 
reduction in pore size traps the drug, sequestering it inside the interior of the mat.  
Extending the drug release studies for long-term evaluation (days to weeks) is required to 
confirm our supposition that as the mat swells to its maximum size; the drug release 
kinetics will plateau; and then increase as the PGA, PCL and PLGA continue to hydrolyze 
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thus releasing more of the drug.  This degradation will lead to additional release of the 
entrapped drug (i.e. residual drug).    
Figure 24: Drug Release Kinetics (Synthetic Polymer/Gelatin blends) 
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Gelatin is soluble in water; whereas the synthetic polymers used in this study have 
no to minimal solubility in water.  The burst in drug release is attributed to the surface 
degradation and dissolution of the gelatin.  The higher release rate of the 50/50 w/w blends 
 
 
57 
in comparison to the 70/30 w/w blends is mainly due to the higher amount of gelatin; 
therefore faster degradation (i.e. hydrolysis) of the matrix.  As the gelatin dissolves, the 
drug is released from the interior of the mat.  The drug release profile for the 50/50 w/w 
blends closely followed the degradation rate profile.  As noted previously, PGA had more 
mass loss in 24 hours and over a 7 day time-frame.  The drug release of DC was also 
higher for the 50/50 w/w PGA/gelatin blend.  More than 50% of the drug was released; 
which may indicate that some of the polymer, however minimal, hydrolyzed as well.  An 
alternative means of evaluation, for example High Performance Liquid Chromatography 
(HPLC), should be employed in lieu of measuring the absorbance to determine the 
concentration of the released drug.   High Performance Liquid Chromatography will allow 
more accurate measurements of drug concentration as it can better partition different 
components of the blend based on their affinity. 55-56   An article by S.M. Sunaric, et al., 
confirms that the peak absorbance for DC is measured at approximately 270 nm and 360 
nm. 57    As indicated in Figure 8, two secondary peaks occur at approximately 270 nm  and 
360 nm; however  a wavelength of 190 nm was used to measure released drug (DC) since 
the maximum absorbance was observed at this point.  Sunaric’s research evaluated 
physiologic degradation of DC in samples with  concentrations of DC ranging from 2.97 to 
17.78 g/mL.  We used UV-Vis to measure concentrations of DC within the same range.  
According to British Pharmacopoeia, the official method for DC determination is liquid 
chromatography with UV detection.  This further confirms the necessity of our future work 
to develop  an HPLC method for analysis of  DC released from our polymer scaffolds.   
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4.5  Conclusions 
Our work demonstrated that gelatin/dendrimer hybrids could be formed using full 
and half generation dendrimers and electrospun with stabilizing synthetic polymers and the 
antibiotic Doxycycline.   The half generation dendrimer produces significantly smaller 
fibers that resemble electrospun collagen and gelatin (fabricated using the same operating 
parameters and conditions).   Three different stabilizing polymers were electrospun with 
gelatin and PAMAM G3.5 dendrimer to form the hybrids.  Synthetic polymer type and 
weight ratio was shown to affect the permeability, porosity, mechanical properties and 
water swelling and degradation of the electrospun mats.  
The increased weight addition of PCL, PGA and PLGA to the gelatin/dendrimer 
hybrids decreased the porosity and permeability of the electrospun mat; corresponding to 
decreased fiber diameters and pore sizes.  Theoretically, decreased fiber diameter should 
result in decreased mechanical stress, however, the stress values for the synthetic polymers 
far exceeds that of gelatin.  Subsequently, the greater the amount of synthetic polymer, the 
higher the stress and strain values of mats.   As proven in statistical analyses and graphical 
representations, the greater the weight ratio of synthetic polymer, the higher stress and 
strain levels the fibers could withstand.   
Poly(glycolic acid) is more hydrophilic than PCL and PLGA.  As such, the 
observed degradation and swelling ratio of the PGA containing mats versus the other two 
was at a much faster rate.    This faster degradation resulted in a higher release of the drug 
in the time-frame analyzed.  Drug release kinetics for all compositions showed a controlled 
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release over a four hour time frame.    A statistical evaluation of the drug release profile for 
each polymer mat was not performed. 
The success of fabricating an electrospun gelatin/dendrimer hybrid that can be 
utilized as a wound dressing with targeted and controlled drug release was demonstrated 
and achieved in this study.  The synthetic polymer type and amount in the 
gelatin/dendrimer hybrids can be varied to influence the morphology, mechanical 
properties, swelling behavior and degradation, thus impacting its drug release kinetics.    
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CHAPTER 5 Summary and Future Work 
 
5.1 Summary 
 In the past few years, significant effort has been devoted to researching  and 
developing nanomedicine and nanotechnology for controlled and targeted drug delivery.  
Presently, biomaterials and drug development has shown an increased focus on 
formulating therapeutic agents in biocompatible nanocomposites, like liposomes, micelle 
systems, nanocapsules and polymer conjugates, that are sub-micron sized.   Advances in 
localized and tissue-specific delivery of small particles, like anticancer drugs, gene vectors, 
antimicrobials and other therapeutic agents, improve drug efficacy and decrease toxicity, 
and reduce drug side-effects. 58-59   The utilization of dendrimers as nano-sized drug 
carriers is expanding.  Dendrimer drug carriers can be easily tailored to deliver both 
hydrophilic and hydrophobic drugs effectively and efficiently.  Dendrimers exhibit surface 
charges that can be exploited to control pH and temperature sensitivity, as well as 
electrospun product characteristics.    However, the research in developing 
gelatin/dendrimer hybrids for use as a wound dressing is limited.  
 Gelatin must usually be electrospun and cross-linked to acquire the mechanical 
properties and suitable characteristics as a TE scaffold. 60  In this study, gelatin/dendrimer 
and synthetic polymer matrices were formed by electrospinning and characterized to 
quantify their physical morphology,  gas and nutrient flow capability, as well as swelling 
behavior, degradation rate and drug release kinetics.    The gelatin/dendrimer hybrids that 
were fabricated show promise as a  bioactive dressing to treat chronic wounds.  They are 
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highly adaptable, and exhibit the properties necessary to maintain a moist wound bed to 
promote wound healing.  Additionally, the controlled and targeted release of Doxycycline 
has the potential to facilitate wound healing by inhibiting MMPs that degrade the 
reconstituted ECM.    
The polymer matrix can be engineered to control wound bed moisture by altering 
synthetic polymer type and weight ratio.  Leveraging the amount of gelatin allows better 
swelling behavior and moisture retention.  Wound bed moisture is critical to promote 
wound healing and ensure adequate nutrient and gas exchange, as well as cell migration, 
within the wound.    The electrospun mat also mimics the native ECM, which theoretically, 
should foster cell adhesion, migration and subsequently proliferation.  The attractive 
features and easy adaptability of the gelatin/dendrimer hybrid developed in this study will 
enable its application as a bioactive dressing to promote wound healing.   
 
5.2 Future Work 
 This study attempted to characterize the physical properties, swelling, degradation 
and drug release profiles of gelatin/dendrimer hybrids for biomedical applications as a 
wound dressing.    Doxycycline has been shown to inhibit MMPs, which are at excessive 
levels in chronic ulcers.  However, this activity was not evaluated in this study.  Studies 
designed to evaluate the impact of DC, released to the wound bed, will be conducted in our 
future work.  Assays to  measure the level of degradative enzyme contained in wounds 
covered by the proposed gelatin/hybrid and those using a control will be evaluated.  In 
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vitro studies of the dressing’s ability to provide a bacteria-free environment to facilitate 
wound healing will also be conducted.   
The wound healing process is complex and involves interactions of various cells 
and matrix components to create a provisional matrix, a platform by which cells can 
migrate and adhere to, leading to eventual closure of the wound.  Wound closure, i.e. re-
epithelialization, involves the controlled migration of fibroblasts and keratinocytes.  
Recent research has shown that the inclusion of basic fibroblast growth factor (FGF) and 
transforming growth factor beta (TGF-) accelerates cell growth and wound healing. 61     
Human skin equivalents have been utilized to assess the acceleration of wound healing and 
the impact of additives like growth factors and proteins like collagen in wound dressings.    
In a study by Schneider and Wang, the rate of wound contraction was successfully 
measured and accelerated by the inclusion of epidermal growth factor (EGF) in electrospun 
silk fibroin scaffolds. 62   Cell interaction and proliferation studies were not conducted to 
assess the bioactivity of the dressing and its ability to facilitate or accelerate wound 
healing.  Expanding this project to include in vitro and in vivo studies evaluating the 
migration and proliferation of fibroblasts and keratinocytes is a necessary milestone in our 
future work.  
Chronic wounds including diabetic foot ulcers, pressure ulcers, and venous leg 
ulcers have been shown to have abundant biofilm communities.  In a study by James, et al., 
chronic and acute wounds were evaluated for biofilms and the bacterial microorganisms 
inhabiting these wounds were characterized. 63    Sixty-percent (60%) of the chronic wound 
specimens that were evaluated by this group contained biofilms, compared to only 6% of 
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the acute wound specimens.  Further, molecular analyses of chronic wound specimens 
examined in their evaluation revealed diverse polymicrobial communities and the presence 
of bacteria, including strictly anaerobic bacteria, not revealed by culture.  
Bacterial biofilm prevalence in chronic wounds adds further complexity in trying to 
accelerate wound healing.  Very few antibiotics have been shown to effectively mitigate or 
eradicate biofilms. 64-65   Bacterial vaginosis and urinary tract infections show significant 
biofilm formation, which contributes to a high rate of recurrence and multiple treatments to 
effect resolution.  The antimicrobials, fleroxacin, ampicillin and gentamicin were found to 
effectively eliminate a lactose-negative, streptomycin-resistant uropathogenic strain of 
Escherichia coli in a study conducted by Morck, et al. 66    Fleroxacin eliminated E. coli 
from the catheter surfaces and from tissues adjacent to the catheter. The ability of 
fleroxacin to effectively eliminate biofilm bacteria from catheter surfaces and adjacent 
tissues shows promise as a potential drug for inclusion in the gelatin/dendrimer hybrid to 
treat chronic wounds.   
We have successfully fabricated and characterized gelatin/dendrimer hybrids for 
use as a potential wound dressing.  Our future work focuses on the cell interaction and 
bioactivity of the gelatin/dendrimer hybrids.  Gentamicin, doxycycline and fleroxacin will 
be encapsulated and/or conjugated to the gelatin/dendrimer hybrids and their efficacy in 
mitigating biofilm formation in chronic wounds is also a major focus in our future work.  
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Appendix 
 
One-way ANOVA: Stress versus Blend 
 
Analysis of Variance for Stress   
Source     DF        SS        MS        F        P 
Blend       6    80.313    13.385    34.62    0.000 
Error      35    13.531     0.387 
Total      41    93.844 
                                   Individual 95% CIs For Mean 
                                   Based on Pooled StDev 
Level       N      Mean     StDev  ----------+---------+---------+------ 
gel(con)    6    1.5622    0.2947         (--*---)  
PCLGel55    6    2.7703    0.7967                 (--*---)  
PCLGel73    6    2.2948    0.5554              (--*---)  
PGAGel55    6    0.7168    0.3456   (---*--)  
PGAGel73    6    3.7103    0.6732                       (---*--)  
PLGAGl55    6    0.6157    0.2645   (--*---)  
PLGAGl73    6    4.6003    1.0167                             (---*--)  
                                   ----------+---------+---------+------ 
Pooled StDev =   0.6218                    1.5       3.0       4.5 
 
Tukey's pairwise comparisons 
 
    Family error rate = 0.0500 
Individual error rate = 0.00356 
 
Critical value = 4.42 
 
Intervals for (column level mean) - (row level mean) 
 
          gel(con)    PCLGel55    PCLGel73    PGAGel55    PGAGel73    PLGAGl55 
 
PCLGel55     -2.3301 
             -0.0862 
 
PCLGel73     -1.8546     -0.6465 
              0.3893      1.5975 
 
PGAGel55     -0.2766      0.9315      0.4560 
              1.9673      3.1755      2.7000 
 
PGAGel73     -3.2701     -2.0620     -2.5375     -4.1155 
             -1.0262      0.1820     -0.2935     -1.8715 
 
PLGAGl55     -0.1755      1.0327      0.5572     -1.0208      1.9727 
              2.0685      3.2766      2.8011      1.2231      4.2166 
 
PLGAGl73     -4.1601     -2.9520     -3.4275     -5.0055     -2.0120     -5.1066 
             -1.9162     -0.7080     -1.1835     -2.7615      0.2320     -2.8627 
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One-way ANOVA: Strain versus Blend 
 
Analysis of Variance for Strain   
Source     DF        SS        MS        F        P 
Blend       6   40.7154    6.7859   214.97    0.000 
Error      35    1.1048    0.0316 
Total      41   41.8203 
                                   Individual 95% CIs For Mean 
                                   Based on Pooled StDev 
Level       N      Mean     StDev  --+---------+---------+---------+---- 
gel(con)    6    0.0545    0.0136   (-*-)  
PCLGel55    6    0.2878    0.0910      (-*)  
PCLGel73    6    0.0912    0.0221   (-*-)  
PGAGel55    6    0.0567    0.0153   (-*-)  
PGAGel73    6    2.6607    0.3479                                   (-*-)  
PLGAGl55    6    0.1612    0.0534    (-*-)  
PLGAGl73    6    1.8353    0.2965                         (-*-)  
                                   --+---------+---------+---------+---- 
Pooled StDev =   0.1777            0.00      0.80      1.60      2.40 
 
Tukey's pairwise comparisons 
 
    Family error rate = 0.0500 
Individual error rate = 0.00356 
 
Critical value = 4.42 
 
Intervals for (column level mean) - (row level mean) 
 
          gel(con)    PCLGel55    PCLGel73    PGAGel55    PGAGel73    PLGAGl55 
 
PCLGel55     -0.5539 
              0.0873 
 
PCLGel73     -0.3573     -0.1239 
              0.2839      0.5173 
 
PGAGel55     -0.3228     -0.0894     -0.2861 
              0.3184      0.5518      0.3551 
 
PGAGel73     -2.9268     -2.6934     -2.8901     -2.9246 
             -2.2856     -2.0522     -2.2489     -2.2834 
 
PLGAGl55     -0.4273     -0.1939     -0.3906     -0.4251      2.1789 
              0.2139      0.4473      0.2506      0.2161      2.8201 
 
PLGAGl73     -2.1014     -1.8681     -2.0648     -2.0993      0.5047     -1.9948 
             -1.4602     -1.2269     -1.4236     -1.4581      1.1459     -1.3536 
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One-way ANOVA: FibrDiam versus Blend 
 
Analysis of Variance for FibrDiam 
Source     DF        SS        MS        F        P 
Blend       5    29.383     5.877     7.84    0.000 
Error     174   130.342     0.749 
Total     179   159.724 
                                   Individual 95% CIs For Mean 
                                   Based on Pooled StDev 
Level       N      Mean     StDev  ----+---------+---------+---------+-- 
PCLgel55   30    2.0340    0.7261               (----*----)  
PCLgel73   30    1.8980    0.9277            (-----*----)  
PGAgel55   30    1.7330    0.8528          (----*----)  
PGAgel73   30    2.6623    1.0652                         (----*-----)  
PLGAgl55   30    1.7890    0.7689           (----*----)  
PLGAgl73   30    1.3167    0.8084   (----*----)  
                                   ----+---------+---------+---------+-- 
Pooled StDev =   0.8655              1.20      1.80      2.40      3.00 
 
Tukey's pairwise comparisons 
 
    Family error rate = 0.0500 
Individual error rate = 0.00441 
 
Critical value = 4.08 
 
Intervals for (column level mean) - (row level mean) 
 
          PCLgel55    PCLgel73    PGAgel55    PGAgel73    PLGAgl55 
 
PCLgel73     -0.5087 
              0.7807 
 
PGAgel55     -0.3437     -0.4797 
              0.9457      0.8097 
 
PGAgel73     -1.2730     -1.4090     -1.5740 
              0.0164     -0.1196     -0.2846 
 
PLGAgl55     -0.3997     -0.5357     -0.7007      0.2286 
              0.8897      0.7537      0.5887      1.5180 
 
PLGAgl73      0.0726     -0.0634     -0.2284      0.7010     -0.1724 
              1.3620      1.2260      1.0610      1.9904      1.1170 
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